The programmed cell death 1 (PD-1) pathway is an important regulator of immune
responses in peripheral tissues, including abnormal situations such as the tumor …

Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have
diversified treatments and improved responses and survival for chemotherapy refractory …

Simple Summary The natural compound sulforaphane is highly popular among tumor
patients, since it is suggested to prevent oncogenesis and cancer progression. However …

Abstract Objective Bladder cancer (BCa) is a highly lethal urological malignancy
characterized by its notable histological heterogeneity. Autophagy has swiftly emerged as a …

Urothelial carcinoma (UC) is the most common histologic type of urinary bladder cancer, and
muscle-invasive UC shows aggressive behaviors. Programmed cell death-1 (PD …

Introduction High recurrence rates, frequent surveillance strategies, and current
multidisciplinary treatment approaches make urothelial carcinoma of bladder (UCB) one of …

Muscle-invasive urothelial carcinoma (MIUC) is the most common type of bladder
malignancy in humans, but also in dogs that represent a naturally occurring model for this …

肌层浸润性膀胱癌在膀胱癌中约占25%~ 30%, 目前标准治疗方式为膀胱癌根治术,
并需同时行盆腔淋巴结清扫及尿道改流术, 但其存在手术难度大, 术后并发症多 …

Background The therapeutic armamentarium of bladder cancer has been recently enriched
with the introduction of new therapies including immune checkpoint inhibitors, receptor …

Systemic therapy is the mainstay of treatment for metastatic urothelial carcinoma (UC).
Responses to first-line platinum-based therapy tend to be short-lived with potential toxicity …